Baici A, Hörler D, Moser B, Hofer H O, Fehr K, Wagenhäuser F J
Department of Rheumatology, University Hospital, Zurich, Switzerland.
Rheumatol Int. 1992;12(3):81-8. doi: 10.1007/BF00290259.
Chondroitin sulfate was administered orally to six healthy volunteers, six patients with rheumatoid arthritis and six patients with osteoarthritis. Blood was collected at intervals before and after treatment and the glycosaminoglycan concentration was analyzed in serum using a sensitive assay based on the metachromatic reaction with 1,9-dimethylmethylene blue. The glycosaminoglycan concentration in serum before and after ingestion of chondroitin sulfate was statistically unchanged in all of the subjects studied. We suggest that chondroprotection by orally administered chondroitin sulfate is a biologically and pharmacologically unfounded theory. Any possible benefit to osteoarthritic patients after ingestion of chondroitin sulfate should be sought at the gastrointestinal rather than at the plasmatic or articular cartilage level.
向6名健康志愿者、6名类风湿性关节炎患者和6名骨关节炎患者口服硫酸软骨素。在治疗前后定期采集血液,并使用基于与1,9-二甲基亚甲基蓝的异染反应的灵敏检测方法分析血清中的糖胺聚糖浓度。在所有研究对象中,摄入硫酸软骨素前后血清中的糖胺聚糖浓度在统计学上无变化。我们认为,口服硫酸软骨素实现软骨保护是一种缺乏生物学和药理学依据的理论。硫酸软骨素摄入后对骨关节炎患者可能存在的任何益处,应在胃肠道层面而非血浆或关节软骨层面探寻。